W. Fox. General considerations in the choice and management of regimens of chemotherapy for pulmonary tuberculosis.Bull. Int. Union Tuberc.
W. Fox and D. A. Mitchison. Short course chemotherapy for pulmonary tuberculosis.Am. Rev. Resp. Dis.
D. A. P. Evans. Genetic variations in the acetylation of isoniazid and other drugs.Ann. N.Y. Acad. Sci.
B. N. La Du. Isoniazid and pseudocholinesterase polymorphisms.Fed. Proc.
J. H. Peters. Genetic factors in relation to drugs.Ann. Rev. Pharmacol.
G. A. Ellard. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis.Clin. Pharmacol. Ther. (in press, 1976).
G. A. Ellard and P. T. Gammon. The pharmacokinetics of isoniazid metabolism in man. In M. Hejzlar, M. Semonsky, and S. Masak (eds.),Advances in Antimicrobial and Anti-neoplastic Chemotherapy, Urban and Schwarzenberg, Munich, 1972, pp. 45–46.
G. A. Ellard, P. T. Gammon, and S. M. Wallace. The determination of isoniazid and its metabolites acetylisoniazid, monoacetylhydrazine, diacetylhydrazine, isonicotinic acid and isonicotinylglycine in serum and urine.Biochem. J.
H. McKennis, Jr., A. S. Yard, J. H. Weatherby, and J. A. Hagy. Acetylation of hydrazine and the formation of 1,2-diacetylhydrazinein vivo.J. Pharmacol. Exp. Ther.
A. Viznerová, Z. Sláviková, and G. A. Ellard. The determination of the acetylator pheno-type of tuberculosis patients in Czechoslovakia using sulphadimidine.Tubercle
D. A. P. Evans, P. B. Storey, and V. A. McKusick. Further observations on the determination of isoniazid inactivator phenotype.Bull. Johns Hopkins Hasp.
G. A. Ellard, V. R. Aber, P. T. Gammon, D. A. Mitchison, S. Lakshminarayan, K. M. Citron, W. Fox, and R. Tall. Pharmacology of some slow-release preparations of isoniazid of potential use in intermittent treatment of tuberculosis.Lancet
G. A. Ellard, P. T. Gammon, and H. Tiitinen. Determination of the acetylator phenotype using matrix isoniazid.Tubercle
H. Varley.Practical Clinical Biochemistry, 3rd ed., Heinemann, London, 1962, p. 634.
R. Gelber, P. Jacobsen, and L. Levy. A study of the availability of six commercial formulations of isoniazid.Clin. Pharmacol. Ther.
J. H. Peters, K. S. Miller, and P. Brown. Studies on the metabolic basis for the genetically determined capacities for isoniazid inactivation in man.J. Pharmacol. Exp. Ther.
150: 298–304 (1965).
J. W. Jenne, F. M. MacDonald, and E. Mendoza. A study of the renal clearances, metabolic inactivation rates, and serum fall-off interaction of isoniazid and para-amino salicylic acid in man.Am. Rev. Resp. Dis.
J. G. Wagner.Biopharmaceutics and Relevant Pharmacokinetics, Drug Intelligence Publications, Hamilton, Ill., 1971, Chap. 38, pp. 292–296.
A. J. Cummings, B. K. Martin, and G. S. Park. Kinetic considerations relating to the accrual and elimination of drug metabolites.Brit. J. Pharmacol. Chemother.
J. R. Mitchell, U. P. Thorgeirsson, M. Black, J. A. Timbrell, W. R. Snodgrass, W. Z. Potter, D. J. Jollow, and H. R. Keiser. Increased incidence of isoniazid hepatitis in rapid acetylators: Possible relation to hydrazine metabolites.Clin. Pharmacol. Ther.
G. A. Ellard, P. T. Gammon, F. Polansky, A. Viznerová, I. Havlik, and W. Fox. Further studies on the pharmacology of a slow-release preparation of isoniazid (Smith and Nephew HS 82) of potential use in the intermittent treatment of tuberculosis.Tubercle
L. C. Dymond and D. W. Russell. Rapid determination of isonicotinic acid hydrazide in whole blood with 2,4,5-trinitrobenzenesulphonic acid.Clin. Chim. Acta
H. G. Boxenbaum, G. S. Jodhka, A. C. Ferguson, S. Riegelman, and T. R. MacGregor. The influence of bacterial gut hydrolysis on the fate of orally administered isonicotinuric acid in man.J. Pharmacokin. Biopharm.
G. Levy and L. P. Ansel. Kinetics of competitive inhibition of salicylic acid conjugation with glycine in man.Biochem. Pharmacol.
J. H. Peters and V. E. Hayes. Comparative studies on the metabolism of isoniazid and isoniazid hydrazones in the dog.Arch. Int. Pharmacodyn. Ther.
F. Skrabal, R. N. Arnot, and G. F. Joplin. Equations for the prediction of normal values for exchangeable sodium, exchangeable potassium, extracellular fluid volume, and total body water.Brit. Med. J.
G. A. Ellard, P. T. Gammon, and H. Tiitinen. Determination of the acetylator phenotype from the ratio of the urinary excretion of acetylisoniazid to acid-labile isoniazid: A study in Finnish Lappland.Tubercle
A. S. Yard and H. McKennis, Jr. Aspects of the metabolism of isoniazid and acetylisoniazid in the human and dog.J. Med. Pharm. Chem.
J. W. Jenne. Partial purification and properties of the isoniazid transacetylase in human liver: Its relationship to the acetylation ofp-aminosalicylic acid.J. Clin. Invest.
W. W. Weber and S. N. Cohen. The mechanism of isoniazid acetylation by humanN- acetyltransferase.Biochim. Biophys. Acta
W. W. Weber, S. N. Cohen, and M. S. Steinberg. Purification and properties ofN-acetyltransferase from mammalian liver.Ann. N.Y. Acad. Sci.
L. H. Schmid. The problem of the rapid inactivator of isoniazid.Bull. Int. Union Tuberc.
L. Eidus, M. M. Hodgkin, A. H. E. Hsu, and O. Schaeffer. Pharmacokinetic studies with an isoniazid slow-releasing matrix preparation.Am. Rev. Resp. Dis.